Growing Asia-Pacific presence for life sciences business

A fully-owned subsidiary of York-based listed life sciences company Optibiotix Health has signed an exclusive agreement to distribute its product in the Philippines.

ProBiotix has struck the deal with CTC Far East Philippines Inc, a subsidiary of the CTC Group, for its proprietary formulation – CholBiome®x3, which fights high cholesterol and high blood pressure.

OptiBiotix specialises in developing compounds to tackle obesity, high cholesterol, diabetes and skincare.

An Optibiotix spokesman said the exclusivity in the deal announced today would be subject to minimum order quantities and a multi-year business plan to improve security of income and revenue growth.

He added: “CTC Group is the global business network group of the Koen Visser Corporation.

“CTC Group is a global life science partner-provider of innovative product solutions for food, beverage, personal care products, and health and wellness.

“The Philippines is a country with an expanding population of over 100 million and an emerging economy with annual GDP growth rates above 6% sustained over the last five years (World Bank).

“Cardiovascular disease is the leading cause of death in the country, with high blood pressure affecting almost 20% of its population (WHO).”

Steve Prescott, CEO of ProBiotix, said: “We are pleased to announce this agreement with CTC, which will expand ProBiotix’s presence in the emerging Asia-Pacific region.

“CTC was chosen as our partner for CholBiome®_x3 product introduction in the Philippines because of their extensive knowledge of the local market and consistent track record successfully launching new products.”